Bruker Daltonics Appoints Michael Schubert as Executive Vice President and Ian Sanders as Vice President

Bruker Daltonics Inc. today announces two promotions to
further strengthen its senior management team.
   Dr. Michael Schubert has been promoted to Executive Vice President
of the Bruker Daltonics group. He retains his previous
responsibilities for Bruker Daltonics' global R&D management, as well
as his function as Managing Director (Geschaeftsfuehrer) of Bruker
Daltonik GmbH, located in Bremen and Leipzig, Germany. In addition,
Dr. Schubert now also assumes responsibility for the Company's
life-science mass spectrometry business in the Americas. Dr. Schubert
joined Bruker Daltonics in 1991, and has held several project and R&D
management positions. In 2002, he became Managing Director of Bruker
Daltonik GmbH, and in 2004 Vice President for R&D of Bruker Daltonics.
He holds a doctorate from the University of Hamburg in physics.
   Ian Sanders, Ph.D., has been promoted to Vice President for
European Life Science Sales, a function that he has previously managed
as an Assistant Vice President. He also continues in his role as
Managing Director of Bruker Daltonik GmbH. Dr. Sanders joined Bruker
Daltonics in 2000 following a ten-year career in drug discovery
research for both large pharmaceutical and venture biotechnology
companies. Initially responsible for the UK business, in 2002 his role
expanded to manage life-science sales in the UK, Scandinavia and The
Netherlands. In 2004, he became Assistant Vice President for European
Life-Science Sales, and in 2005, Managing Director of Bruker Daltonik
GmbH. He holds a Ph.D. in drug discovery technology from The
University of Bath, UK.
   Frank Laukien, President and CEO of Bruker BioSciences, said: "I
am very pleased for Michael and Ian to assume additional management
responsibilities at Bruker Daltonics. Both of them have excellent
track records and I expect that in their expanded roles they will
contribute even more strongly to our corporate goals. By focusing on
customers, on technological and business innovation, and on
operational excellence we drive to continue our above
industry-standard revenue growth while reaching substantial
profitability."

   ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

   Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker
Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer
and provider of life science and advanced materials research tools
based on x-ray technology. Bruker Daltonics is a leading developer and
provider of innovative life science tools based on mass spectrometry.
Bruker Daltonics also offers a broad line of nuclear, biological and
chemical (NBC) detection products for defense and homeland security.
For more information, please visit www.bruker-biosciences.com

   CAUTIONARY STATEMENT

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, exposure to currency
fluctuations, changes in governmental regulations, capital spending
and government funding policies, FDA and other regulatory approvals to
the extent applicable, competition, the intellectual property of
others, patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the SEC,
including, without limitation, our respective annual reports on Form
10-K for the year ended December 31, 2004, our most recent quarterly
reports on Form 10-Q, and our current reports on Form 8-K. We disclaim
any intent or obligation to update these forward-looking statements.